Suárez-García, InésMoreno, CristinaRuiz-Algueró, MartaPérez-Elías, María JesúsNavarro, MartaDíez Martínez, MarcosViciana, PompeyoPérez-Martínez, LauraGórgolas, MiguelAmador, Conchade Zárraga, Miguel AlbertoJarrín, InmaCohort of the Spanish HIV/AIDS Research Network (CoRIS)2023-02-092023-02-092020-07-20http://hdl.handle.net/10668/15964The aim of this study was to investigate the effectiveness and tolerability of the combination elvitegravir/cobicistat/tenofovir/emtricitabine plus darunavir (EVG/COB/TFV/FTC + DRV) in treatment-experienced patients from the cohort of the Spanish HIV/AIDS Research Network (CoRIS). Treatment-experienced patients starting treatment with EVG/COB/TFV/FTC + DRV during the years 2014-2018 and with more than 24 weeks of follow-up were included. TFV could be administered either as tenofovir disoproxil fumarate or tenofovir alafenamide. We evaluated virological response, defined as viral load (VL)  We included 39 patients (12.8% women). At baseline, 10 (25.6%) patients had VL  EVG/COB/TFV/FTC + DRV was well tolerated and effective in treatment-experienced patients with undetectable viral load as a simplification strategy, allowing once-daily, two-pill regimen with three antiretroviral drug classes. Effectiveness was low in patients with detectable viral loads.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Cohort studiesDarunavirHIV infectionHighly active antiretroviral therapyAdultAnti-HIV AgentsCobicistatDarunavirDrug Therapy, CombinationEmtricitabineFemaleHIV InfectionsHIV-1HumansMaleMiddle AgedQuinolonesSpainTenofovirTreatment OutcomeViral Loadresearch article32690099open access10.1186/s12981-020-00302-21742-6405PMC7372769https://doi.org/10.1186/s12981-020-00302-2https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372769/pdf